Literature DB >> 6243863

Evidence that danazol inhibits gonadotropin-induced ovarian steroidogenesis at a point distal to gonadotropin-receptor interaction and adenosine 3',5' cyclic monophosphate formation.

M Menon, S Azhar, K M Menon.   

Abstract

The action of danazol on 125I-human chorionic gonadotropin (hCG) binding, gonadotropin-stimulated adenosine 3',5' cyclic monophosphate (cAMP) accumulation and progesterone production has been investigated in luteinized rat ovaries. Preincubation of luteal cells for short periods of time with increasing concentrations of danazol caused a significant inhibition of gonadotropin-stimulated steroidogenesis. The inhibitory effect of danazol was both concentration and time dependent. Danazol also reduced progesterone production in response to cholera enterotoxin and 8 bromo-adenosine-cAMP, but it had no effect on hCG, luteinizing hormone, and cholera enterotoxin stimulated cAMP formation. Similarly danazol did not affect 125I-hCG binding as assessed by the equilibrium dissociation constant (Kd) and number of hormone-binding sites on the luteal cell surface. These results suggest that in intact luteal cells danazol inhibits steroidogenesis at a point distal to hormone-receptor interaction and cAMP formation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6243863     DOI: 10.1016/0002-9378(80)90683-3

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

1.  Endometriosis--continuing conundrum.

Authors: 
Journal:  Br Med J       Date:  1980-10-04

2.  Effects of danazol on steroidogenesis and gonadotropic responsiveness in isolated human preovulatory follicular cells.

Authors:  J H Olsson; B Dennefors; L Nilsson
Journal:  J Endocrinol Invest       Date:  1986-04       Impact factor: 4.256

3.  Effects of an androgenic derivative on pre-established mammary tumours chemically induced in the rat.

Authors:  E Escrich; T Ribalta; J Muntané; M C Ruiz de Villa; J Murillo; S Saez
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.